@prefix biolink: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix dct: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "\"The use of Heparin Sodium in 0.45% Sodium Chloride Injection or Heparin Sodium in 5% Dextrose Injection is contraindicated in patients with the following conditions: History of Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT) [see Warnings and Precautions ( 5.3 Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions ( 6.1 In whom suitable blood coagulation tests -- e.g., the whole blood clotting time, partial thromboplastin time, etc., -- cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) [see Warnings and Precautions ( 5.5 An uncontrolled bleeding state [see Warnings and Precautions ( 5.2 History of Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT) ( 4 Known hypersensitivity to heparin or pork products ( 4 In whom suitable blood coagulation tests cannot be performed at appropriate intervals ( 4\"";
biolink:provided_by ;
biolink:relation schema:MedicalContraindication .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "BFfWhquQcweGbbmG3CXU8oZvIQBybUOWUtk1EdkcsogC6s9C+k/IT4m/+KuuGGMX6yntISm/TM4HeF/Mq9z1j8eNiyFwgSt+4+qS0PTSd1lbl7X+yyDUFurTwqvhxKRwfCjQ3pjFBSsbIZTmGOm5XFI+m5SNYm0vPp5Jowu0GTU=";
npx:hasSignatureTarget this: .
this: dct:created "2021-08-23T18:57:43.341+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-1468-3557;
ns1:wasCreatedFromProvenanceTemplate ;
ns1:wasCreatedFromPubinfoTemplate ;
ns1:wasCreatedFromTemplate .
}